Please login to the form below

overactive bladder

This page shows the latest overactive bladder news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... There are no currently available FDA-approved gene therapy treatments for overactive bladder.

Latest news

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

The proceeds will fund phase III trials of its overactive bladder treatment candidate vibegron, which it in-licensed last year from Merck &Co. ... Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB
Allergan pushes on with Botox for depression

overactive in depression. ... Aside from its use as a wrinkle treatment Botox is already approved to treat various medical conditions, including chronic migraine, excessive sweating and overactive bladder among others, and is Allergan's
Size matters?

Clinical trials are ongoing to test its application against overactive bladder and migraine.
Astellas sells dermatology unit to Leo for €675m

The overarching aim is to prepare for the forthcoming patent expiries on big-selling drugs Vesicare (solifenacin succinate) for overactive bladder and cancer therapy Tarceva (erlotinib).
Eylea's UK launch earns Bayer PMEA success

strategy. Other companies recognised in the category included Astellas, which was highly commended for its launch of overactive bladder treatment Betmiga, while Astellas and Shire were both finalists.

More from news
Approximately 4 fully matching, plus 46 partially matching documents found.

Latest Intelligence

Astellas: Ten years young

In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new
Allergan and taking a specialised approach

In addition to migraine and adult spasticity, its approved indications include overactive bladder, muscle stiffness in elbow, wrist and fingers, muscle problems in the eye, crow's feet lines and severe
Interview: Kay Drake and Naoki Okamura, Astellas

For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
Interview: Ken Jones, Astellas Pharma Europe

Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

emotive boosts health economics and outcomes research team

His MSc project involved performing a health economic evaluation of the cost-effectiveness of different overactive bladder treatments available in the UK. ... The appointment of Trishal, with his specific expertise in visual science and overactive bladder

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Medical Writer: Salary is DOE

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager: Negotiable

Associate Scientific Director: Salary TBC

Account Director or Senior Account Director: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Sudler London - Account Director: Competitive

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Writer, Healthcare Advertising, London: Excellent package

Sudler London - Senior Medical Writer: Competitive

Senior Training Manager - Surrey: Competitive Salary &Bonus

Graduate Scientific Editor: DOE

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Systematic Review Lead- London: Negotiable

Account Manager- 4 days per week or full-time: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Market Access Consultant - Greater Manchester: Negotiable

Healthcare PR Senior Account Manager: Salary TBC

Senior Account Manager – Healthcare Advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....